Emphysema Treatment Market - Global Forecast 2025-2032

The emphysema treatment market is witnessing substantial shifts, propelled by evolving therapeutic approaches and strategic technological advancements. Industry stakeholders must stay attuned to a landscape shaped by innovation, policy changes, and emerging patient needs, ensuring alignment with critical regional and operational dynamics.

Market Snapshot: Emphysema Treatment Market Overview

The emphysema treatment market grew from USD 6.83 billion in 2024 to USD 7.32 billion in 2025, with a projected CAGR of 7.22% to reach USD 11.94 billion by 2032. Expanding demand is primarily driven by the prevalence of chronic respiratory conditions, advancements in treatment modalities, and increased adoption of next-generation inhalation and biologic therapies. With positive regulatory dynamics and investment in digital health integration, the market’s momentum demonstrates robust growth potential for organizations seeking to bolster their therapeutic portfolios.

Scope & Segmentation of the Emphysema Treatment Market

This report offers an in-depth analysis across diverse emphysema treatment strategies and evolving technology trends, providing comprehensive coverage of market drivers and challenges across major geographies.

• Treatment Types: Pharmacological interventions (antibiotics, bronchodilators, corticosteroids, mucolytics); surgical approaches (bullectomy, lung transplantation, volume reduction surgery, valve therapy).
• Drug Classes: Includes anticholinergics, beta-agonists, and combination drugs.
• Therapy Line: Considers adjunctive, first-line, maintenance (e.g., combination therapy, long-acting agents), and rescue (short-acting agents) therapies.
• Route of Administration: Covers inhalation (dry powder inhaler, metered dose inhaler, nebulizer, soft mist inhaler), intravenous (infusion, injection), and oral (capsule, solution, tablet) methods.
• Dosage Forms: Includes capsule, inhaler, nebulizer, solution, and tablet.
• Distribution Channels: Analyzes hospital, online, and retail pharmacy dynamics.
• Product Types: Differentiates between branded and generic therapeutics.
• Regional Analysis: Coverage encompasses the Americas (North America, Latin America), Europe, Middle East, Africa, and Asia-Pacific – focusing on infrastructure maturity, regulatory pathways, and distribution networks.
• Company Landscape: Major market participants include GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd, Viatris Inc., Chiesi Farmaceutici S.p.A., Sunovion Pharmaceuticals Inc., Sandoz International GmbH, and Cipla Limited.

Key Takeaways for Senior Decision-Makers

• Innovation in precision medicine and digital platforms is tailoring emphysema treatment to patient subgroups, enabling individualized care and superior outcomes.
• Device innovation, including next-generation inhalers and minimally invasive surgical tools, is driving improved patient adherence and broadening access to advanced therapies.
• Public and private sector collaborations are fundamental in expanding specialized care, particularly in regions with evolving healthcare delivery systems.
• Shifting reimbursement structures and regulatory agility are enhancing the speed of market entry and broadening patient access to transformative therapies.
• Strategic partnerships—spanning biotech, device manufacturers, and academic institutions—are catalyzing R&D momentum and supporting comprehensive disease management frameworks.

Tariff Impact: US Policy Changes Reshape Supply Chains

Recent US tariff increases on pharmaceutical and medical device imports have introduced cost pressures across the emphysema therapeutics supply chain. Manufacturers are adopting domestic sourcing strategies and evaluating alternative materials to minimize supply interruptions and manage price stability. Efforts to establish localized production and enhance procurement agility are enabling companies to address emerging regulatory complexities while maintaining resilient, tariff-aware supply models.

Methodology & Data Sources

Findings are based on a combination of expert interviews, targeted surveys, and cross-verified secondary data. This encompasses insights from healthcare professionals, manufacturing executives, and patient advocacy groups, ensuring comprehensive and validated perspectives on market opportunities and operational trends.

Why This Report Matters

• Enables informed investment and R&D prioritization by illustrating evolving therapies and their market implications for senior executives.
• Supports robust strategic planning by mapping regulatory, reimbursement, and technological shifts across critical global regions.

Conclusion

This report empowers leaders to anticipate market transformation, align strategy with therapeutic innovation, and strengthen competitive positioning in the dynamic emphysema treatment sector.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.